Healthcare >> CEO Interviews >> February 27, 2015
Gregory D. Cash is President, CEO and Director of BioSig Technologies, Inc. He is an experienced executive and a seasoned industry veteran. He has over 30 years of business experience and has been Chief Executive Officer of several companies, both public and privately held, as well as run global business units of larger companies. Prior to joining BioSig, Mr. Cash was President and CEO of Argent International, a life sciences consulting firm. Previous positions include President and Chief Executive Officer of NeuroTherm, Inc.; President and Chief Executive Officer as well as a director of HeartSine Technologies, Inc.; President, Vascular Therapy and New Businesses for Sorin Group based in Milan, Italy; President and Chief Executive Officer and a director of Vasomedical, Inc., a Nasdaq-traded public company; Corporate Vice President, Datascope Corporation, and President of its subsidiary, InterVascular, Inc.; President and Chief Operating Officer of Eminent Technology Partners, and Chief Executive Office of its subsidiary, Eminent Research Systems; Vice President and General Manager, Vascular Therapies for U.S. Surgical Corporation; and spent five years with Boston Scientific Corporation, ultimately as Vice President, Cardiology Sales and Marketing, Europe. He began his career at Medtronic, Inc., where he served 14 years in increasingly senior sales and marketing positions. Mr. Cash has lived and worked as an expatriate in London, England; Hong Kong; Paris, France; and Milan, Italy, and speaks French, German and Italian. He holds a B.A. in international marketing and business administration from the College of St. Thomas in St. Paul, Minnesota. Profile
TWST: Can you begin by providing an overview of the company?
Mr. Cash: BioSig Technologies is a medical device company that has developed a proprietary technology platform designed to